CDC Panel Holds Meeting to Discuss J&J Vaccine Pause – NBC Los Angeles

U.S. health officials are considering the next steps in investigating a small number of abnormal blood clots in those who receive them. Johnson & Johnsons COVID-19 Vaccine — A single dose that many countries have been eagerly waiting to help speed up antivirus control.

It is not clear whether very rare reports (so far, 6 out of more than 7 million vaccinations in the United States) are really related to the J & J vaccine.But Government recommended suspension of J & J vaccination on Tuesday, Only one week later European regulators have declared that such blood clots are rare but potentially risky with the AstraZeneca vaccine. Shots created in a similar way, but not yet approved for use in the United States

Overall, COVID-19 poses a much greater risk of death and hospitalization than the potential thrombotic threat, according to experts. The next step will be Wednesday, when an advisor to the US Centers for Disease Control and Prevention will discuss how to handle the J & J vaccine at a public meeting, and authorities will try to figure out exactly what is happening.

“At this point, we consider these events to be very rare, but we’re still not sure if we’ve heard of all possible cases because this syndrome may not be easily recognized. “CDC Director Rochelle Walensky said before the meeting.

Blood clot concerns can undermine public confidence in vaccines that many wanted to help some of the most difficult to reach in places like poor countries and homeless shelters in the United States.

“We know we’re fighting COVID-19,” said Dr. Peter Marks, Vaccine Officer at the Food and Drug Administration. But when it comes to side effects, “in the United States, we’re not very tolerant of friendly fire.”

According to Marks, his agency has reduced J & J timeouts rather than making sure doctors know how to recognize and treat abnormal conditions because of reported blood clots. Recommended. He said one of the six women was in a complex condition due to treatment with an anticoagulant called heparin — a treatment that the government warned doctors to avoid.

Walensky states that the ability to find such rare reports and act swiftly “indicates that the safety system we are implementing is working.”

Dr. Peter Marks, director of the FDA Center for Biologics Evaluation and Research, explains why the FDA recommended suspending Johnson & Johnson vaccines, despite the extremely rare appearance of blood clots. ..

The J & J retreat has brought COVID-19 to nearly 3 million deaths worldwide, including more than 560,000 deaths in the United States and tens of thousands of new infections reported daily, averaging about 1,000 A person is dead.

So far, the J & J vaccine has been a minor player in US vaccination. More than 122 million Americans have been vaccinated at least once, most of them by injections with Moderna or Pfizer, and nearly 23% are fully vaccinated.

Both companies plan to achieve 300 million doses each from mid-July to late July. Federal health officials have emphasized that the Moderna and Pfizer vaccines show no signs of abnormal blood clots.

Immunization is slowing in Europe, where many countries struggle to supply. J & J postponed some of its deliveries to Europe in its blood clot assessment, but Poland said it would use the batches it already had. European healthcare regulators will publish their own assessment of J & J’s blood clot issue next week.

The United States has set up a centralized system to track safety during the deployment of the COVID-19 vaccine. We knew that when millions of people rolled up their sleeves, they could have side effects that were so rare that they didn’t occur in thousands of studies.

The clot in question is not a typical clot. They occur in abnormal parts of the body, such as the veins that drain blood from the brain. Also, the patient’s platelet levels are abnormally low, cells that help form blood clots, usually associated with bleeding rather than coagulation.

Dr. Anne Schuchat, Chief Deputy Director of the CDC, discusses what to monitor if you have recently been vaccinated with the Johnson & Johnson COVID-19 vaccine.

When these strange blood clots were discovered after AstraZeneca vaccination, Norwegian and German scientists said that some people experienced an abnormal immune response and formed antibodies that nullify platelets. Raised the possibility. That’s a theory, as the United States is currently investigating J & J’s reports.

Health officials are careful not to confuse the usual flu-like symptoms that occur one or two days after many COVID-19 vaccinations with blood clot concerns. Problematic thrombotic symptoms such as severe headaches and severe abdominal pain occurred approximately 1 to 3 weeks after the J & J shot.

Headlines can be horrifying for vaccinated people. Hori Brennon, 35, who was shot at J & J three or four weeks ago in Reno, Nevada, showed flu-like symptoms after vaccination and asked her brother, a doctor, what to think.

He told her to monitor her symptoms, but don’t worry too much, “but obviously it worries you,” Vrenon said.


The Associated Press’s Department of Health Sciences is supported by the Department of Science Education at the Howard Hughes Medical Institute. AP is solely responsible for all content.

CDC Panel Holds Meeting to Discuss J&J Vaccine Pause – NBC Los Angeles Source link CDC Panel Holds Meeting to Discuss J&J Vaccine Pause – NBC Los Angeles

Related Articles

Back to top button